Results for tag: "Firazyr"

Firazyr is a drug used to treat hereditary angioedema (HAE), a rare, genetic disorder that causes episodes of swelling in the face, extremities, gastrointestinal tract, and airway. It is the only approved subcutaneous treatment for HAE in the United States and Europe. Firazyr is a recombinant human C1 esterase inhibitor (rhC1INH) that works by inhibiting the activity of the C1 esterase enzyme, which is responsible for the swelling associated with HAE. The Firazyr market is composed of a variety of companies that specialize in the development and manufacture of drugs for immune disorders. These companies include Shire, CSL Behring, and Pharming Group, among others. They are focused on developing treatments for HAE and other immune disorders, such as lupus, rheumatoid arthritis, and multiple sclerosis. Additionally, these companies are researching new treatments for HAE, such as gene therapy and monoclonal antibodies. Show Less Read more